Title and Organization:
Robert Blum is President, CEO, and a member of the Board of Cytokinetics (NASDAQ: CYTK), a biopharmaceutical company he founded in 1998. Prior to Cytokinetics, Robert held senior positions in business and commercial development at COR Therapeutics from 1991 to 1998 and performed roles of increasing responsibility in sales, marketing, and business planning at Marion Laboratories and Syntex Corporation beginning in 1981. Robert served on the faculty at the Center for BioEntrepreneurship at University of California, San Francisco, co-chaired the BIO Business Development Committee and is a frequent lecturer on matters of business development and finance. He currently serves as the Chairman of the Board of Directors of Gamida Cell (NASDAQ:GMDA).
Robert served on the National Board of the American Committee of the Weizmann Institute of Science and established the Blum Family Venture Philanthropy Fund to propel basic science discoveries at the Institute with potential to benefit the Israeli life sciences economy. In addition, he established the Tikkun Olam Youth Science Prizes for Bay Area schools designed to further science education and exploration in the spirit of repairing the world. He served on the Board of the Jewish Community Federation of San Francisco and founded and chaired its Business Leadership Council. He currently serves on the Board of San Francisco Jewish Family and Children’s Services and has served on the Boards of San Francisco’s Contemporary Jewish Museum and the Anti-Defamation League.
Robert was named a Henry Crown Fellow in the 2005 class of the Aspen Institute in recognition of his leadership in corporate and civic responsibilities. He is a member of the Aspen Global Leadership Network and has moderated seminars related to science, health, and technology at Aspen Action Forums.
Mr. Blum received B.A. degrees in Human Biology and Economics from Stanford University and an M.B.A. from Harvard Business School.